Authors' objectives: Treatment of obesity is based on four pillars: dietary, pharmacological and surgical treatment, and changes in lifestyle. In recent years the use of pharmacological agents capable of inhibiting gastric motility has been suggested. Botulinum toxin type A is an inhibitor of acetylcholinemediatedperistalsis, which is the main agent for gastric motility. The specifi c objectives of this report are focused on determining the effectiveness and safety of administering botulinum toxin type A in the treatment of morbid obesity. Two randomized trials of mild-high methodological quality were identifi ed that compared treatment with botulinum toxin A with a placebo. One of the trials demonstrated a statistically signifi cant decrease in body weight in the group treated with botulinum toxin A. The group treated with botulinum toxin A lost 11.8 kg vs. 5.5 kg lost by those receiving saline (p <0.0002). Endoscopic administration of botulinum toxin A did not cause any adverse effects due to the procedure or the substance administered.

Project Status: Completed

URL for project: https://www.aetsa.org/publicacion/toxina-botulinica-a-en-el-tratamiento-de-la-obesidad-morbida/

Year Published: 2011

URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2009-2-4_ToxBotulinica.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Spain

Organisation Name: Andalusian Health Technology Assessment Area

Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309

Contact Name: aetsa.csalud@juntadeandalucia.es

Contact Email: aetsa.csalud@juntadeandalucia.es

Copyright: Andalusian Agency for Health Technology Assessment (AETSA)